Kymo Therapeutics

About:

Kymo Therapeutics has a goal to advance Metabrain’s kynurenine metabolism (KMO) inhibitors towards clinical proof of concept.

Top Investors: Medicxi

Description:

Kymo Therapeutics’s ambition is to move forward Metabrain Research’s proprietary program on kynurenine metabolism (KMO) inhibitors towards clinical proof of concept, before seeking partners to complete development and ensure commercialization.

Total Funding Amount:

$11M

Headquarters Location:

Hereford, Herefordshire, United Kingdom

Founded Date:

2016-05-23

Founders:

Number of Employees:

1-10

Last Funding Date:

2016-10-06

IPO Status:

Private

Industries: